• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Recent Advances in the Application of Phosphoramidous Acid, N,N-bis(1-methylethyl)-, 2-cyanoethyl phenylmethyl ester (CAS: 196197-29-2) in Chemical Biology and Pharmaceutical Research

Phosphoramidous acid, N,N-bis(1-methylethyl)-, 2-cyanoethyl phenylmethyl ester (CAS: 196197-29-2) is a critical reagent in oligonucleotide synthesis, particularly in the preparation of phosphoramidite building blocks for DNA and RNA synthesis. Recent studies have highlighted its pivotal role in the development of novel therapeutic oligonucleotides, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers. This research brief synthesizes the latest findings on the applications, mechanisms, and innovations associated with this compound, providing a comprehensive overview for researchers in the chemical biology and pharmaceutical fields.

A 2023 study published in Nucleic Acids Research demonstrated the compound's enhanced efficiency in solid-phase oligonucleotide synthesis, achieving higher coupling yields and reduced side reactions compared to traditional phosphoramidite reagents. The research team attributed this improvement to the steric hindrance provided by the isopropyl groups, which minimizes unwanted side reactions during the coupling step. These findings have significant implications for the scalable production of therapeutic oligonucleotides, where yield and purity are paramount.

In the realm of siRNA therapeutics, a breakthrough study in Journal of Medicinal Chemistry (2024) utilized 196197-29-2-derived phosphoramidites to synthesize chemically modified siRNAs with improved nuclease resistance and pharmacokinetic properties. The modified siRNAs showed a 3-fold increase in plasma half-life and enhanced target gene silencing in vivo, addressing one of the major challenges in RNAi therapeutics. This advancement opens new possibilities for the treatment of previously undruggable targets in oncology and genetic disorders.

Recent innovations in the compound's application have extended beyond nucleic acid therapeutics. A 2024 ACS Chemical Biology publication reported its use in the synthesis of phosphorodiamidate morpholino oligomers (PMOs), showing superior delivery efficiency and target engagement compared to conventional PMO synthesis methods. The study demonstrated that the unique properties of 196197-29-2-derived intermediates facilitated the incorporation of cell-penetrating moieties, significantly improving tissue distribution in preclinical models of neuromuscular diseases.

Quality control and analytical methods for 196197-29-2 have also seen significant advancements. A recent Analytical Chemistry article (2023) described a novel LC-MS/MS method capable of detecting impurities at levels below 0.1%, addressing regulatory concerns for GMP-grade production. The method's high sensitivity and specificity have been adopted by several leading oligonucleotide manufacturers, ensuring the consistent quality of therapeutic products derived from this key intermediate.

Looking forward, the compound's versatility continues to inspire new applications. Emerging research presented at the 2024 International Conference on Chemical Biology suggests potential uses in the synthesis of nucleic acid-based sensors and diagnostics. These developments, coupled with ongoing improvements in synthetic methodologies, position 196197-29-2 as a cornerstone reagent in the rapidly expanding field of nucleic acid therapeutics and beyond.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)